BioMimetic Therapeutics, Inc. to Report Third Quarter 2012 Financial Results on November 5

  BioMimetic Therapeutics, Inc. to Report Third Quarter 2012 Financial Results
  on November 5

Business Wire

FRANKLIN, Tenn. -- November 01, 2012

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company
plans to release its financial results for the three and nine months ended
September 30, 2012, on Monday, November 5 after the close of market. The
Company will host a conference call and audio webcast to discuss its third
quarter financial results, product development programs and business
activities at 4:30 p.m. EST the same day.

The conference call may be accessed on November 5, 2012, by dialing (877) 224
- 4059 for U.S. and Canadian callers (passcode:  56458053). The international
dial in number is (706) 902 - 2069, and the same passcode applies.
Participants should dial in 10 minutes prior to the call.

A live webcast of the conference call will be available on the Investor
Relations section of BioMimetic’s website at The webcast
will be archived for at least 30 days following the call.

About BioMimetic Therapeutics

BioMimetic Therapeutics (NASDAQ: BMTI) is a biotechnology company specializing
in the development and commercialization of clinically proven products to
promote the healing of musculoskeletal injuries and diseases, including
therapies for orthopedics, sports medicine and spine applications. All
Augment^® branded products are based upon recombinant human platelet-derived
growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the
body’s principal agents to stimulate and direct healing and regeneration.
Through the commercialization of this patented technology, BioMimetic seeks to
become the leading company in the field of regenerative medicine by providing
new treatment options for the repair of bone, cartilage, tendons and

BioMimetic has received regulatory approvals to market Augment^® Bone Graft in
Canada, Australia and New Zealand for use in foot and ankle fusion
indications. Augment is pending regulatory decisions in the U.S. and European
Union for similar indications. The Company also markets a bone graft
substitute line of products for orthopedic indications called Augmatrix^TM
Biocomposite Bone Graft.

For further information, contact Kearstin Patterson, senior director of
corporate communications, at 615-236-4419.


BioMimetic Therapeutics, Inc.
Kearstin Patterson
Corporate Communications
615-236-4419 (office)
615-517-6112 (mobile)
Press spacebar to pause and continue. Press esc to stop.